Key result
Combined TP antagonism and COX-1 inhibition reduces atherogenesis and vascular inflammation in mice vs monotherapy.
Why the study?
Does the combination of a COX-1 inhibitor and a TP antagonist reduce atherogenesis more than either drug alone in LDLR KO mice on a high-fat diet?
Population
Low-density lipoprotein receptor-deficient (LDLR KO) mice on a high-fat diet
Comparison
Combination of selective COX-1 inhibitor and TP… vs SC560 alone, BM-573 alone, or control
Design
Preclinical
Authors
Loading...
Combination therapy merits testing in additional atherosclerosis models; leaves open any human translation.
Does the combination of a COX-1 inhibitor and a TP antagonist reduce atherogenesis more than either drug alone in LDLR KO mice on a high-fat diet?
The addition of a thromboxane receptor antagonist to COX-1 inhibition synergistically reduces atherogenesis and vascular inflammation in a mouse model.
Cyrus et al. (2006) studied Atherogenesis. Combination of SC560 (COX-1 inhibitor) and BM-573 (TP antagonist) vs. SC560 alone or BM-573 alone was evaluated on Atherogenesis. The addition of a TP antagonist (BM-573) to a COX-1 inhibitor (SC560) significantly decreased atherogenesis and vascular inflammation in LDLR KO mice compared to either drug alone.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: